Compare Incyte Corporation (INCY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Omnicom Group Inc. — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Omnicom Group Inc. trades at $82.4 (market cap $23.48B). The key difference: Incyte Corporation and Omnicom Group Inc. are close in size by market cap, and Omnicom Group Inc. pays a 3.88% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OMC | |
|---|---|---|
Market Cap | $23.11B | $23.48B |
Sector | Health | Media |
52-Week High | $118.52 | $85.80 |
52-Week Low | $67.38 | $67.27 |
Enterprise Value | $19.13B | $30.70B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Omnicom (OMC) trades at $82.36, up 0.77% with a bullish technical outlook and strong cash flow generation. The stock shows attractive valuation metrics with a P/E of 12.16 and P/S of 0.95, though 2025 saw a net loss of $54.5 million despite revenue growth to $17.27 billion. Recent developments include major client wins with IBM and Netflix partnerships, positioning the company for future growth in digital advertising.
OMC presents a compelling value opportunity with 28% upside to the $105.75 consensus price target, supported by dividend payments and institutional confidence. Key risks include intense industry competition and the need to sustain profitability improvements after the 2025 loss. The upcoming Q2 2026 earnings report on July 28 will be critical for validating the company's turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
